AAAAAA
Results:
1-15
|
Results: 15
Authors:
BOSSO JA
Citation: Ja. Bosso, CONTROLLING PNEUMOCOCCAL RESISTANCE TO PENICILLIN, American journal of health-system pharmacy, 54(5), 1997, pp. 527-527
COMPATIBILITY OF FILGRASTIM WITH SELECTED ANTIMICROBIAL DRUGS DURING SIMULATED Y-SITE ADMINISTRATION
Authors:
HALL PD
YUI D
LYONS S
BOSSO JA
Citation: Pd. Hall et al., COMPATIBILITY OF FILGRASTIM WITH SELECTED ANTIMICROBIAL DRUGS DURING SIMULATED Y-SITE ADMINISTRATION, American journal of health-system pharmacy, 54(2), 1997, pp. 185-189
Authors:
BOSSO JA
HARDIN TC
Citation: Ja. Bosso et Tc. Hardin, ADDED QUALIFICATIONS FOR PHARMACY SPECIALISTS - ANOTHER PERSPECTIVE, The Annals of pharmacotherapy, 31(12), 1997, pp. 1535-1536
Authors:
BOSSO JA
Citation: Ja. Bosso, IS PHARMACOTHERAPY A SPECIALTY - AND THE EMPERORS NEW CLOTHES - AUTHORS REPLY, Pharmacotherapy, 17(5), 1997, pp. 1048-1049
Authors:
BOSSO JA
STRINGER KA
HAMMOND RW
DIAZ DR
HUTCHINSON RA
MUNROE WP
RAASCH RH
SISCA TS
SUMMERFIELD MR
Citation: Ja. Bosso et al., PHARMACOTHERAPY SPECIALTY CERTIFICATION EXAMINATION .5. FURTHER EXPERIENCE AND REFINEMENT, Pharmacotherapy, 17(2), 1997, pp. 399-406
Authors:
BOSSO JA
Citation: Ja. Bosso, IS PHARMACOTHERAPY A SPECIALTY, Pharmacotherapy, 17(2), 1997, pp. 413-414
Authors:
MANDURU M
MIHM LB
WHITE RL
FRIEDRICH LV
FLUME PA
BOSSO JA
Citation: M. Manduru et al., IN-VITRO PHARMACODYNAMICS OF CEFTAZIDIME AGAINST PSEUDOMONAS-AERUGINOSA ISOLATES FROM CYSTIC-FIBROSIS PATIENTS, Antimicrobial agents and chemotherapy, 41(9), 1997, pp. 2053-2056
Authors:
MANDURU M
MIHM LB
WHITE RL
FRIEDRICH LV
FLUME PA
BOSSO JA
Citation: M. Manduru et al., COMPARATIVE BACTERICIDAL ACTIVITY OF CEFTAZIDIME AGAINST ISOLATES OF PSEUDOMONAS-AERUGINOSA AS ASSESSED IN AN IN-VITRO PHARMACODYNAMIC MODEL VERSUS THE TRADITIONAL TIME-KILL METHOD, Antimicrobial agents and chemotherapy, 41(11), 1997, pp. 2527-2532
Authors:
MANDURU M
FARIELLO A
WHITE RL
FOX JL
BOSSO JA
Citation: M. Manduru et al., STABILITY OF CEFTAZIDIME SODIUM AND TEICOPLANIN SODIUM IN A PERITONEAL-DIALYSIS SOLUTION, American journal of health-system pharmacy, 53(22), 1996, pp. 2731-2734
Authors:
CRAMER GW
BOSSO JA
Citation: Gw. Cramer et Ja. Bosso, THE ROLE OF DORNASE ALFA IN THE TREATMENT OF CYSTIC-FIBROSIS, The Annals of pharmacotherapy, 30(6), 1996, pp. 656-661
Authors:
BOSSO JA
LIU Q
EVANS WE
RELLING MV
Citation: Ja. Bosso et al., CYP2D6, N-ACETYLATION, AND XANTHINE-OXIDASE ACTIVITY IN CYSTIC-FIBROSIS, Pharmacotherapy, 16(5), 1996, pp. 749-753
Authors:
WHITE RL
BURGESS DS
MANDURU M
BOSSO JA
Citation: Rl. White et al., COMPARISON OF 3 DIFFERENT IN-VITRO METHODS OF DETECTING SYNERGY - TIME-KILL, CHECKERBOARD, AND E-TEST, Antimicrobial agents and chemotherapy, 40(8), 1996, pp. 1914-1918
Authors:
BOSSO JA
PRINCE RA
FOX JL
Citation: Ja. Bosso et al., COMPATIBILITY OF ONDANSETRON HYDROCHLORIDE WITH FLUCONAZOLE, CEFTAZIDIME, AZTREONAM, AND CEFAZOLIN SODIUM UNDER SIMULATED Y-SITE CONDITIONS, American journal of hospital pharmacy, 51(3), 1994, pp. 389-391
Authors:
LINDSAY CA
BOSSO JA
Citation: Ca. Lindsay et Ja. Bosso, OPTIMIZATION OF ANTIBIOTIC-THERAPY IN CYSTIC-FIBROSIS PATIENTS - PHARMACOKINETIC CONSIDERATIONS, Clinical pharmacokinetics, 24(6), 1993, pp. 496-506
Authors:
HULS CE
PRINCE RA
SEILHEIMER DK
BOSSO JA
Citation: Ce. Huls et al., PHARMACOKINETICS OF CEFEPIME IN CYSTIC-FIBROSIS PATIENTS, Antimicrobial agents and chemotherapy, 37(7), 1993, pp. 1414-1416
Risultati:
1-15
|